{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was reported only when the number of participants analyzed were \\>= 3.","groupId":"OG000","spread":"NA","value":"0.643"},{"comment":"Standard deviation was reported only when the number of participants analyzed were \\>= 3.","groupId":"OG002","spread":"NA","value":"3.77"},{"comment":"Standard deviation was reported only when the number of participants analyzed were \\>= 3.","groupId":"OG003","spread":"NA","value":"1.00"},{"comment":"Standard deviation was reported only when the number of participants analyzed were \\>= 3.","groupId":"OG004","spread":"NA","value":"0.375"},{"groupId":"OG005","spread":"0.755","value":"0.799"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"description":"The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received IV 5 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG000","title":"5 mcg/kg"},{"description":"Participants received IV 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG001","title":"10 mcg/kg"},{"description":"Participants received IV 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG002","title":"20 mcg/kg"},{"description":"Participants received IV 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG003","title":"30 mcg/kg"},{"description":"Participants received IV 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG004","title":"40 mcg/kg"},{"description":"Participants received IV 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG005","title":"50 mcg/kg"}],"paramType":"MEAN","populationDescription":"The PK Population consisted of all participants who received any amount of moxetumomab pasudotox and had a sufficient number of serum concentration measurements for computing PK parameters. The \"Overall Number of Participants Analyzed\" denotes the number of participants evaluated for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: pre-infusion; at 15 min during the infusion; at the end of infusion (approximately 5-7 minutes before the end of infusion); and at 1, 1.5, 2, 4, 8, and 12 h post infusion","title":"Terminal Phase Elimination Half Life (t1/2) of Moxetumomab Pasudotox for Cycle 1 on Day 1","type":"PRIMARY","unitOfMeasure":"hours"}